Netilmicin sulfate is a semisynthetic, water-soluble aminoglycoside antibiotic derived from sisomicin. It is bactericidal and primarily active against aerobic gram-negative bacilli. It is less ototoxic and nephrotoxic compared to other aminoglycosides like gentamicin and amikacin, making it a preferred choice in specific clinical scenarios where toxicity is a concern. It is available in injectable form (IV/IM) and as ophthalmic solutions/drops.
Adult: For systemic infections: 4-6 mg/kg/day in 2-3 equally divided doses (every 8 or 12 hours). For UTIs: 3-4 mg/kg/day in 2 divided doses. Dosing must be individualized based on ideal body weight and renal function.
Note: For IV use: Dilute in 50-100 mL of compatible IV fluid (NS, D5W) and infuse over 30-60 minutes. For IM use: Administer deep into a large muscle mass. Ophthalmic: Instill 1-2 drops into the affected eye(s) every 1-2 hours initially, reducing frequency as infection improves. NEVER administer intravenously as a bolus.
Netilmicin binds irreversibly to the 30S ribosomal subunit of susceptible bacteria, specifically to the 16S rRNA and proteins of the A-site. This binding interferes with the initiation complex, causes misreading of the mRNA template, and inhibits translocation. The result is the incorporation of incorrect amino acids into the growing peptide chain, leading to the production of non-functional or toxic proteins and ultimately bacterial cell death.
Pregnancy: Category D (US FDA). Aminoglycosides cross the placenta. There is a risk of fetal ototoxicity (8th cranial nerve damage). Use only if the potential benefit justifies the potential risk to the fetus. Avoid use in pregnancy unless for life-threatening infections where safer alternatives are not available.
Driving: May cause dizziness or vertigo. Patients should be cautioned about operating machinery or driving until they know how the medication affects them.
| Other Nephrotoxic Drugs (Vancomycin, Amphotericin B, Cisplatin, Loop Diuretics like Furosemide) | Additive or synergistic nephrotoxicity and ototoxicity. | Major |
| Other Neurotoxic Drugs (Colistin, Polymyxin B) | Increased risk of neuromuscular blockade and respiratory depression. | Major |
| Neuromuscular Blocking Agents (Succinylcholine, Tubocurarine) | Potentiation of neuromuscular blockade, prolonged apnea. | Major |
| Penicillins (e.g., Carbenicillin, Ticarcillin) - when mixed in vitro | Chemical inactivation of netilmicin. Administer separately. | Moderate |
| Indomethacin in Preterm Neonates | May reduce renal clearance of netilmicin, increasing toxicity risk. | Moderate |
Same composition (Netilmicin (10mg)), different brands: